List of Contents

Cancer Diagnostics Market Size, Share, and Trends 2024 to 2034

The global cancer diagnostics market size was USD 143.62 billion in 2023, estimated at USD 156.25 billion in 2024 and is anticipated to reach around USD 354.66 billion by 2034, expanding at a CAGR of 8.54% from 2024 to 2034.

  • Last Updated : September 2024
  • Report Code : 1194
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Diagnostics Market 

5.1. COVID-19 Landscape: Cancer Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Diagnostics Market, By Product

8.1. Cancer Diagnostics Market, by Product Type, 2024-2034

8.1.1. Consumables (Antibodies, Kits & Reagents, Probes, Other Consumables)

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Instruments (Pathology-based Instruments, Slide Staining Systems, Tissue Processing Systems, Cell Processors, Others)

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Imaging Instruments (CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Nuclear Imaging Systems)

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Biopsy Instruments

8.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Cancer Diagnostics Market, By Technology

9.1. Cancer Diagnostics Market, by Technology, 2024-2034

9.1.1. IVD Testing (PCR, ISH, IHC, NGS, Microarrays, Flow Cytometry, Immunoassays)

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Imaging (MRI, CT, PET, Mammography, Ultrasound)

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Biopsy Technique

9.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Cancer Diagnostics Market, By Application 

10.1. Cancer Diagnostics Market, by Application, 2024-2034

10.1.1. Breast Cancer

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Colorectal Cancer

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Cervical Cancer

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Lung Cancer

10.1.4.1. Market Revenue and Forecast (2021-2034)

10.1.5. Prostate Cancer

10.1.5.1. Market Revenue and Forecast (2021-2034)

10.1.6. Skin Cancer

10.1.6.1. Market Revenue and Forecast (2021-2034)

10.1.7. Blood Cancer

10.1.7.1. Market Revenue and Forecast (2021-2034)

10.1.8. Kidney Cancer

10.1.8.1. Market Revenue and Forecast (2021-2034)

10.1.9. Liver Cancer

10.1.9.1. Market Revenue and Forecast (2021-2034)

10.1.10. Pancreatic Cancer

10.1.10.1. Market Revenue and Forecast (2021-2034)

10.1.11. Ovarian Cancer

10.1.11.1. Market Revenue and Forecast (2021-2034)

10.1.12. Others

10.1.12.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Cancer Diagnostics Market, By End Use 

11.1. Cancer Diagnostics Market, by End Use, 2024-2034

11.1.1. Hospitals and Clinics

11.1.1.1. Market Revenue and Forecast (2021-2034)

11.1.2. Diagnostic Laboratories

11.1.2.1. Market Revenue and Forecast (2021-2034)

11.1.3. Diagnostic Imaging Centers

11.1.3.1. Market Revenue and Forecast (2021-2034)

11.1.4. Research Institutes

11.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 12. Global Cancer Diagnostics Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.2. Market Revenue and Forecast, by Technology (2021-2034)

12.1.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.4. Market Revenue and Forecast, by End Use (2021-2034)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.5.4. Market Revenue and Forecast, by End Use (2021-2034)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.1.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.1.6.4. Market Revenue and Forecast, by End Use (2021-2034)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.4. Market Revenue and Forecast, by End Use (2021-2034)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.5.4. Market Revenue and Forecast, by End Use (2021-2034)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.6.4. Market Revenue and Forecast, by End Use (2021-2034)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.7.4. Market Revenue and Forecast, by End Use (2021-2034)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.2.8.2. Market Revenue and Forecast, by Technology (2021-2034)

12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.2.8.4. Market Revenue and Forecast, by End Use (2021-2034)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.4. Market Revenue and Forecast, by End Use (2021-2034)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.5.4. Market Revenue and Forecast, by End Use (2021-2034)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.6.4. Market Revenue and Forecast, by End Use (2021-2034)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.7.4. Market Revenue and Forecast, by End Use (2021-2034)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.3.8.2. Market Revenue and Forecast, by Technology (2021-2034)

12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.3.8.4. Market Revenue and Forecast, by End Use (2021-2034)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.4. Market Revenue and Forecast, by End Use (2021-2034)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.5.4. Market Revenue and Forecast, by End Use (2021-2034)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.6.4. Market Revenue and Forecast, by End Use (2021-2034)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.7.4. Market Revenue and Forecast, by End Use (2021-2034)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Product (2021-2034)

12.4.8.2. Market Revenue and Forecast, by Technology (2021-2034)

12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)

12.4.8.4. Market Revenue and Forecast, by End Use (2021-2034)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.4. Market Revenue and Forecast, by End Use (2021-2034)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)

12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.5.4. Market Revenue and Forecast, by End Use (2021-2034)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Product (2021-2034)

12.5.6.2. Market Revenue and Forecast, by Technology (2021-2034)

12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)

12.5.6.4. Market Revenue and Forecast, by End Use (2021-2034)

Chapter 13. Company Profiles

13.1. Agilent Technologies, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific, Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Illumina, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Becton, Dickinson and Company

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GE Healthcare

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. QIAGEN N.V.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Abbott Laboratories, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Roche Diagnostics

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Siemens Healthcare

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Philips Healthcare

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

13.11. R. Bard, Inc. 

13.11.1. Company Overview

13.11.2. Product Offerings

13.11.3. Financial Performance

13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client